Please login to the form below

Not currently logged in
Email:
Password:

Pharma appointments, April 2012

Recent high-profile moves in the pharmaceutical and healthcare industries
Mover of the month is Werner Wenning, who is returning to Bayer as chairman of its supervisory board.

Mover of the month

  
 Werner Wenning, Bayer

Bayer's former chairman and CEO Werner Wenning is set to return to the German pharma company in the Autumn as chairman of its supervisory board. Wenning was chairman of the company's board of management from 2002 to 2010 and will take over as chairman of the supervisory board from Dr Manfred Schneider in October for a five-year term. Wenning started at Bayer as a trainee, spending nearly 45 years with the company. He helped establish Bayer's Peruvian subsidiary, was seconded for a year to the Treuhandanstalt, the Berlin-based privatisation agency that helped rebuild East Germany's economy after reunification, and served as managing director of Bayer's largest company in Spain. Also nominated for election to the supervisory board are Sue Rataj, who sits on the board of US chemical company Cabot and Thomas Ebeling, current CEO of German media conglomerate ProSiebenSat.1 Media, who also served in senior roles at Novartis between 1998 and 2009.

 


 

AstraZeneca (AZ) will elect Leif Johansson as its new chair following the retirement of Louis Schweitzer in September 2012. Johansson, who is currently chair of Sweden-based telecommunication company Ericsson, will also become non-executive director, effective April 26, 2012. Prior to his appointment at Ericsson in April 2011, Johansson served 14 years as president and CEO of vehicle manufacturer, Volvo. He has an MSc in engineering from Chalmers University of Technology, Sweden, and was a member of the board of Bristol-Myers Squibb until September, 2011. He will be joined on the board by Rexam's CEO Graham Chipchase and chief R&D officer at Unilever Geneviève Berger who will also become non-executive directors. John Varley becomes senior independent non-executive director.

Leif Johansson, AstraZeneca



Brian McNamara, Novartis  

Novartis has promoted Brian McNamara from president Novartis OTC Americas to head of its entire over-the-counter division. McNamara replaces Naomi Kelman who leaves the company. McNamara has been at Novartis OTC since 2004, when he joined as senior VP and general manager of OTC North America.


Dr Charlotte Kremer has moved from Pfizer to Astellas to lead the Japanese pharma company's new global medical affairs organisation, based at Astellas' Illinois headquarters for its Americas operations. Dr Kremer has spent 20 years in the pharmaceutical industry, most recently as VP and therapeutic area head for ophthalmology, PVD, rare diseases and neuroscience at Pfizer. Prior to that she worked at Organon in the Netherlands and the US.




 Dr Charlotte Kremer, Astellas



Anders Spohr, Leo Pharma

Leo Pharma has promoted senior VP Anders Spohr to the position of executive VP for global product supply. He takes over from John Mehlbye at the Denmark-based pharma firm, with Mehlbye to continue on the board of directors of the Leo Foundation. Spohr joined Leo Pharma from Danish biotech Novozymes in December 2011, where he had spent 11 years.


UCB's chief executive Roch Doliveux has been appointed chair of the Innovative Medicines Initiative's (IMI) governing board. He has served as a board member since May 2010 and also sits on the board of one of IMI's founding partners, the European Federation of Pharmaceutical Industries and Associations (EFPIA).


Roch Doliveux, UCB

 

 


Catherine Meaden, ABPI

The Association of the British Pharmaceutical Industry (ABPI) has appointed Catherine Meaden as its head of policy and public affairs. She joins the UK pharma industry body from NHS Direct, where she spent three years as associate director of marketing and communications. Prior to this she held communications roles at the NHS Confederation and Cancer Research UK.

 

 

UCB will appoint Harriet Edelman and Charles-Antoine Janssen as board members on April 26 at the company's general assembly. The Belgium-based pharma firm also confirmed that Karel Boone will step down as chair, to be succeeded by fellow board member Gerhard Mayr. Further changes include the resignation of Alexandre Van Damme from the board, as well as the loss of Thomas Leysen and Gaëtan van de Werve, who have both come to the end of their mandates. Edelman is currently vice chair of Emigrant Bank. Janssen has been at UCB since 2001, holding several management positions.

Jean-Luc Lowinski, global head of animal health at Bayer, has been appointed senior VP, Asia Region, at Sanofi. Based in Shanghai, Lowinski previously served as head of operations in Singapore, India, Thailand, China and Japan during his time at Bayer. In 2003, he was appointed head of Bayer Healthcare, China and subsequently became head of Bayer Healthcare, Asia Pacific, and president, Bayer Yakuhin, Japan in 2007.

Lundbeck has promoted Jacob Tolstrup to VP business development. He moves from VP finance and administration at the company's American subsidiary, Lundbeck US. He has also served as VP investor relations and communications; divisional director, investor relations and communications; and financial analyst and planner.

Inovio Pharmaceuticals has appointed former president of Merck Vaccines Dr Adel Mahmoud to its board of directors. Dr Mahmoud spent six years in his vaccines position at Merck, from 1999 to 2005, overseeing the development of human papillomavirus (HPV) vaccine Gardasil. He is professor of the department of molecular biology and the Woodrow Wilson School of Public and International Affairs at Princeton University.

Abbott India has appointed the former head of its nutrition arm Rehan Khan as its new managing director. Khan takes over from Vivek Mohan, who moves to a global role within the US pharma group's established products division as a senior director of global integrated health. Khan will hold the managing director's post for five years with effect from May 15, 2012 and has been appointed to the board of Abbott India.

Onyx Pharmaceuticals has hired Luigi Costa as VP and head of Europe. Costa joins the US-headquartered biopharma from Amgen where he was VP and general manager of France. Based at Onyx's European headquarters in Zug, Switzerland, Costa will report to Dr Helen Torley, executive VP and chief commercial officer. He had been at Amgen since 2003 in roles including general manager for Switzerland and Italy.

AVI BioPharma's senior VP and chief business officer Paul Medeiros has joined Mundipharma as head of corporate and business development. Medeiros also joins the executive leadership team at the UK-based group, which controls Napp in the UK and has associated companies in other European countries. Other roles in his 19-year career in the biopharma industry include VP, global licensing and strategic alliances for Schering-Plough and positions in sales and marketing at Merck & Co.

The UK's National Institute for Health and Clinical Excellence (NICE) has appointed Prof Mark Baker and Alexia Tonnel as directors. Prof Baker will replace departing Prof Peter Littlejohns as director of the centre for clinical practice, while Tonnel becomes director of evidence resources following the retirement of Dr Fergus Macbeth. Prof Baker has been involved with the NICE Guidelines Programme for nearly a decade and has worked as a consultant adviser to the body since 2009. Tonnel has been a programme director at NICE since 2010.

The European Health Technology Institute for Socio-Economic Research (EHTI) has appointed Yves Verboven as executive director. He joins from eyecare specialists Alcon. Since the beginning of 2012, he has also been consultant for Eucomed, the trade body of the medical devices industry. Verboven replaces Rosanna Tarricone, who will hold the role of scientific director.

Tony Mauro, president of Mylan Pharmaceuticals, has been elected chair of the US-based Generic Pharmaceutical Association (GPhA). Mauro, previously the trade body's vice chair, replaces Watson Pharmaceuticals' president and CEO Paul Bisaro.

Matt Lowe has left Grünenthal to join UK communications group Creston Health as head of digital. He will oversee digital activities at Red Door Communications, Rock Medical Communications, Grapevine and Pan Advertising.

Aron Caplan has joined WPP's Suder London healthcare communications agency as director of planning. He was formerly proprietor and director at Withinsight Strategic Planning and previously worked with Rapp Consumer Heath, Euro RSCG Life and Digitas Health.



Related links

FAQ: How do I get my move listed

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics